Literature DB >> 26692101

MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.

Andrej Besse1,2, Jiri Sana1,2, Radek Lakomy1, Leos Kren3, Pavel Fadrus4, Martin Smrcka4, Marketa Hermanova5, Radim Jancalek6, Stefan Reguli7, Radim Lipina7, Marek Svoboda1, Pavel Slampa8, Ondrej Slaby9,10.   

Abstract

Glioblastoma multiforme (GBM) is the most aggressive form of brain tumor. Despite radical surgery and radiotherapy supported by chemotherapy, the disease still remains incurable with an extremely low median survival rate of 12-15 months from the time of initial diagnosis. The main cause of treatment failure is considered to be the presence of cells that are resistant to the treatment. MicroRNAs (miRNAs) as regulators of gene expression are involved in the tumor pathogenesis, including GBM. MiR-338 is a brain-specific miRNA which has been described to target pathways involved in proliferation and differentiation. In our study, miR-338-3p and miR-338-5p were differentially expressed in GBM tissue in comparison to non-tumor brain tissue. Overexpression of miR-338-3p with miRNA mimic did not show any changes in proliferation rates in GBM cell lines (A172, T98G, U87MG). On the other hand, pre-miR-338-5p notably decreased proliferation and caused cell cycle arrest. Since radiation is currently the main treatment modality in GBM, we combined overexpression of pre-miR-338-5p with radiation, which led to significantly decreased cell proliferation, increased cell cycle arrest, and apoptosis in comparison to irradiation-only cells. To better elucidate the mechanism of action, we performed gene expression profiling analysis that revealed targets of miR-338-5p being Ndfip1, Rheb, and ppp2R5a. These genes have been described to be involved in DNA damage response, proliferation, and cell cycle regulation. To our knowledge, this is the first study to describe the role of miR-338-5p in GBM and its potential to improve the sensitivity of GBM to radiation.

Entities:  

Keywords:  GBM; Glioblastoma multiforme; Radiation resistance; miRNA; miRNA338-5p

Mesh:

Substances:

Year:  2015        PMID: 26692101     DOI: 10.1007/s13277-015-4654-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

1.  MIR152, MIR200B, and MIR338, human positional and functional neuroblastoma candidates, are involved in neuroblast differentiation and apoptosis.

Authors:  Marco Ragusa; Alessandra Majorana; Barbara Banelli; Davide Barbagallo; Luisa Statello; Ida Casciano; Maria Rosa Guglielmino; Laura Rita Duro; Marina Scalia; Gaetano Magro; Cinzia Di Pietro; Massimo Romani; Michele Purrello
Journal:  J Mol Med (Berl)       Date:  2010-06-25       Impact factor: 4.599

Review 2.  DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance.

Authors:  Massimo Squatrito; Eric C Holland
Journal:  Cancer Res       Date:  2011-09-13       Impact factor: 12.701

3.  PP2A-B56ϵ complex is involved in dephosphorylation of γ-H2AX in the repair process of CPT-induced DNA double-strand breaks.

Authors:  Xiuying Li; Anuo Nan; Ying Xiao; Yongzhong Chen; Yandong Lai
Journal:  Toxicology       Date:  2015-03-12       Impact factor: 4.221

4.  Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.

Authors:  Jiri Sana; Lenka Radova; Radek Lakomy; Leos Kren; Pavel Fadrus; Martin Smrcka; Andrej Besse; Jana Nekvindova; Marketa Hermanova; Radim Jancalek; Marek Svoboda; Marian Hajduch; Pavel Slampa; Rostislav Vyzula; Ondrej Slaby
Journal:  Carcinogenesis       Date:  2014-10-16       Impact factor: 4.944

5.  Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

Authors:  Yi Chieh Lim; Tara L Roberts; Bryan W Day; Brett W Stringer; Sergei Kozlov; Shazrul Fazry; Zara C Bruce; Kathleen S Ensbey; David G Walker; Andrew W Boyd; Martin F Lavin
Journal:  Mol Oncol       Date:  2014-06-27       Impact factor: 6.603

Review 6.  MicroRNAs involved in chemo- and radioresistance of high-grade gliomas.

Authors:  Andrej Besse; Jiri Sana; Pavel Fadrus; Ondrej Slaby
Journal:  Tumour Biol       Date:  2013-04-09

7.  MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1.

Authors:  Chunxi Liu; Zhiyu Wang; Yi Wang; Wuwei Gu
Journal:  Mol Cell Biochem       Date:  2014-09-10       Impact factor: 3.396

8.  miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a.

Authors:  Xin Chen; Min Pan; Lulu Han; Hongting Lu; Xiwei Hao; Qian Dong
Journal:  FEBS Lett       Date:  2013-10-15       Impact factor: 4.124

9.  MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons.

Authors:  Armaz Aschrafi; Azik D Schwechter; Marie G Mameza; Orlangie Natera-Naranjo; Anthony E Gioio; Barry B Kaplan
Journal:  J Neurosci       Date:  2008-11-19       Impact factor: 6.167

10.  Ndfip1 regulates nuclear Pten import in vivo to promote neuronal survival following cerebral ischemia.

Authors:  Jason Howitt; Jenny Lackovic; Ley-Hian Low; Adam Naguib; Alison Macintyre; Choo-Peng Goh; Jennifer K Callaway; Vicki Hammond; Tim Thomas; Matthew Dixon; Ulrich Putz; John Silke; Perry Bartlett; Baoli Yang; Sharad Kumar; Lloyd C Trotman; Seong-Seng Tan
Journal:  J Cell Biol       Date:  2012-01-02       Impact factor: 10.539

View more
  19 in total

1.  Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop.

Authors:  Ke Xu; Yueping Zhan; Zeting Yuan; Yanyan Qiu; Haijing Wang; Guohua Fan; Jie Wang; Wei Li; Yijun Cao; Xian Shen; Jun Zhang; Xin Liang; Peihao Yin
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

2.  MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1.

Authors:  Xin-Long Ma; Feng Shang; Wei Ni; Jin Zhu; Bin Luo; Yu-Qi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2018-09-17       Impact factor: 4.553

3.  MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma.

Authors:  Naoshi Nishida; Tadaaki Arizumi; Satoru Hagiwara; Hiroshi Ida; Toshiharu Sakurai; Masatoshi Kudo
Journal:  Liver Cancer       Date:  2016-12-17       Impact factor: 11.740

4.  Methylation of microRNA-338-5p by EED promotes METTL3-mediated translation of oncogene CDCP1 in gastric cancer.

Authors:  Fangbin Zhang; Yan Yan; Xinguang Cao; Jinping Zhang; Yingxia Li; Changqing Guo
Journal:  Aging (Albany NY)       Date:  2021-04-21       Impact factor: 5.682

Review 5.  MicroRNAs, DNA Damage Response, and Cancer Treatment.

Authors:  Mingyang He; Weiwei Zhou; Chuang Li; Mingxiong Guo
Journal:  Int J Mol Sci       Date:  2016-12-12       Impact factor: 5.923

6.  Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data.

Authors:  Liang Liang; Li Gao; Xiao-Ping Zou; Meng-Lan Huang; Gang Chen; Jian-Jun Li; Xiao-Yong Cai
Journal:  Mol Med Rep       Date:  2017-11-21       Impact factor: 2.952

7.  Effects of miR-338 on morphine tolerance by targeting CXCR4 in a rat model of bone cancer pain.

Authors:  Hong-Xia Mei; Min-Hong Zhou; Xing-Wang Zhang; Xi-Xi Huang; Yong-Le Wang; Pei-Fang Wang; Gong-Hao Zhan
Journal:  Biosci Rep       Date:  2017-03-15       Impact factor: 3.840

Review 8.  MicroRNAs Involvement in Radioresistance of Head and Neck Cancer.

Authors:  Parwez Ahmad; Jiri Sana; Marek Slavik; Pavel Slampa; Pavel Smilek; Ondrej Slaby
Journal:  Dis Markers       Date:  2017-02-23       Impact factor: 3.434

9.  The dual-inhibitory effect of miR-338-5p on the multidrug resistance and cell growth of hepatocellular carcinoma.

Authors:  Yang Zhao; Jing Chen; Wenxin Wei; Xinming Qi; Chunzhu Li; Jin Ren
Journal:  Signal Transduct Target Ther       Date:  2018-01-26

10.  Uptake of 18F-FET and 18F-FCH in Human Glioblastoma T98G Cell Line after Irradiation with Photons or Carbon Ions.

Authors:  Francesca Pasi; Marco Giovanni Persico; Federica Eleonora Buroni; Carlo Aprile; Marina Hodolic; Franco Corbella; Rosanna Nano; Angelica Facoetti; Lorenzo Lodola
Journal:  Contrast Media Mol Imaging       Date:  2017-01-16       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.